Is immunotherapy the future of cancer?

23/08/2023

Article by: Camilla Fezzi, on 23 August 2023, at 02:43 pm PDT

Immunotherapy, often hailed as the future of cancer treatments and therapies for various immune diseases, has undergone significant development over the years. This method of treatment harnesses the power of the body's immune system to fight diseases, marking a significant shift from traditional treatments such as chemotherapy and radiation therapy. This article will delve into major milestones in the development of immunotherapy and discuss recent advancements in this promising field.

Historical Developments

The concept of immunotherapy has been around for a long time. One of the earliest forms of immunotherapy can be traced back to the late 19th century when Dr. William B. Coley started developing "Coley's toxins" to treat sarcomas. He injected bacteria into tumors, which prompted an immune response that, in some cases, caused the tumors to regress.

The 20th century saw significant advancements in our understanding of the immune system, propelling the development of immunotherapy. In the late 1970s, the discovery of interleukins, a type of cytokine signaling molecule, opened a new avenue for cancer treatment. The first successful use of interleukins in treating kidney cancer and melanoma occurred in the 1980s.

The Dawn of Monoclonal Antibodies

The 1970s also witnessed another major breakthrough with the development of monoclonal antibodies (mAbs). These laboratory-produced molecules are engineered to serve as substitute antibodies that can restore, enhance, or mimic the immune system's attack on disease cells. mAbs have since become a cornerstone of immunotherapy, with drugs like Rituximab (for lymphomas) and Trastuzumab (for breast cancer) gaining FDA approval in 1997 and 1998, respectively.

The Rise of Checkpoint Inhibitors

The early 21st century saw the introduction of checkpoint inhibitors, a class of drugs that block proteins from inhibiting the immune system's response to cancer cells. The FDA-approved CTLA-4 blocker, Ipilimumab, in 2011, used for treating melanoma. This was followed by the approval of PD-1 inhibitors such as Pembrolizumab and Nivolumab in the mid-2010s.

 Advancements in CAR-T Cell Therapy

Chimeric Antigen Receptor T-cell (CAR-T) therapy represents another major development in immunotherapy. This personalized treatment involves modifying a patient's T-cells (a type of immune cell) to express a receptor specific to the cancer antigen, thereby enabling them to seek out and kill the cancer cells. The first CAR-T therapies, Kymriah and Yescarta, were approved by the FDA in 2017 for certain types of lymphoma.

Vaccines in Immunotherapy

Therapeutic cancer vaccines, which stimulate the immune system to attack certain diseases, have also seen significant advancements. The first therapeutic cancer vaccine, Sipuleucel-T (ProvengeĀ®), was approved by the FDA in 2010 for prostate cancer.

mmunotherapy, a treatment approach that harnesses the body's immune system to fight diseases, has been gaining significant traction in the field of oncology. As research progresses, there is increasing evidence to suggest that immunotherapy could indeed play a pivotal role in the future of cancer treatment. However, it's important to understand that while immunotherapy presents promising potential, it currently complements, rather than replaces, traditional cancer treatments like surgery, radiation, and chemotherapy.

The Promise of Immunotherapy

Immunotherapy has shown remarkable results in several types of cancers that were previously difficult to treat. For instance, checkpoint inhibitors, a type of immunotherapy, have shown significant benefits in treating cancers like melanoma, lung cancer, and kidney cancer. Similarly, CAR-T cell therapies have shown impressive results in treating certain blood cancers. Immunotherapy has certain advantages over traditional cancer treatments. For some patients, it offers long-term control of cancer with fewer side effects than chemotherapy or radiation. It can also be personalized to target specific characteristics of individual patients' tumors, potentially leading to more effective treatment.

Despite its potential, immunotherapy is not a silver bullet for all cancers. Certain types of cancer have not responded well to these therapies, and researchers are still trying to understand why. In addition, while some patients experience minimal side effects, others can suffer severe immune-related adverse events (irAEs). These side effects occur when the immune system, stimulated by the treatment, attacks healthy cells in the body. The cost associated with immunotherapy treatments can also be prohibitive. These treatments, especially personalized ones like CAR-T therapy, can be extremely expensive, hindering widespread accessibility.

The Future of Cancer Treatment: A Multi-pronged Approach

While immunotherapy holds great promise, it's unlikely to completely replace traditional cancer treatments in the foreseeable future. Instead, it's becoming an important part of a multi-pronged approach to cancer treatment. For example, immunotherapy can be used in combination with chemotherapy or radiation to increase effectiveness. This approach, known as combination therapy, is already being used in certain cases and is an active area of research. Moreover, scientists are working to improve existing immunotherapies and develop new ones that will be effective against a wider range of cancers. There's also significant work being done to predict which patients are likely to respond to immunotherapy, aiming to personalize treatment plans and improve patient outcomes.

Recent Developments and Future Directions

The field of immunotherapy continues to evolve rapidly. As of my knowledge cutoff in September 2021, one of the most promising areas of development was the use of 'bispecific antibodies'. These innovative molecules can bind to two different targets at once, potentially improving the ability to target and destroy cancer cells. Other promising research directions include the development of personalized vaccines based on the genetic makeup of a patient's tumor, and the use of 'oncolytic viruses' designed to selectively kill cancer cells.

In conclusion, the development of immunotherapy has been marked by significant scientific breakthroughs, leading to a range of new treatments that have proven effective against various types of cancer and other diseases. As our understanding of the immune system and its interaction with diseases continues to grow, we can expect to see further exciting developments in this field.

Be the first to read what's new in science!